No, they are different compounds with different roles
Semaglutide primarily reduces body fat while helping preserve muscle mass, especially when used as part of a balanced treatment plan
By activating GLP-1 receptors, semaglutide helps: Stimulate insulin production when blood sugar is high Reduce glucagon secretion, which further lowers blood sugar Slow down digestion, promoting a feeling of fullness Decrease appetite by acting on brain centers controlling hunger The FDA has approved Ozempic for the treatment of type 2 diabetes, while Wegovy, a higher-dose formulation of semaglutide, is specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
We now offer another way to administer GLP-1 medication: oral dissolving tablets (ODT)
Intriguingly, one of these studies also showed that longer administrations can lead to a normalization of anxiety and a dissociable improvement in depression-like behavior 158 a pattern that resembles of the mechanisms of action of conventional antidepressants and that may be further suggestive of the activity of GLP-1RAs on the serotonin system 158
